Want to see ADMA full AI Analyst Report?
ADMA Stock Chart & Stats
$8.27
-$0.10(-1.19%)
At close: 4:00 PM EDT
$8.27
-$0.10(-1.19%)
Day’s Range― - ―
52-Week Range$7.21 - $20.46
Previous CloseN/A
Volume2.34M
Average Volume (3M)3.22M
Market Cap
$2.12B
Enterprise Value$2.00K
Total Cash (Recent Filing)$136.02M
Total Debt (Recent Filing)$203.84M
Price to Earnings (P/E)13.2
Beta0.99
Next Earnings
Nov 11, 2026EPS Estimate
0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.72
Shares Outstanding223,984,680
10 Day Avg. Volume2,812,449
30 Day Avg. Volume3,218,944
Financial Highlights & Ratios
PEG Ratio-1.09
Price to Book (P/B)9.11
Price to Sales (P/S)8.52
P/FCF Ratio156.23
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$17.00Price Target Upside105.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.79
Revenue Forecast (FY)$534.36M
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation & FCF ConversionADMA’s recent multi-hundred-million dollar operating and free cash flow, with FCF roughly 85% of net income, indicates durable cash-generation capacity. This supports reinvestment in pipeline, opportunistic buybacks, and debt service, improving resilience through business cycles.
ASCENIV: Durable Revenue Growth And Higher MarginsASCENIV’s rapid adoption and outsized margin contribution materially improves company mix. Higher-margin product mix and yield-enhanced manufacturing make ASCENIV-driven profitability less cyclical, supporting sustainable EBITDA and freeing resources for commercialization and pediatric expansion.
Vertically Integrated Plasma Supply And ManufacturingA mixed model of owned and third-party plasma sourcing plus yield-enhanced manufacturing secures feedstock and improves high-titer utilization. Vertical integration reduces supply risk, stabilizes input costs, and raises manufacturing leverage as commercial volumes scale over the medium term.
Bears Say
Aggressive Pricing In Standard IG MarketSustained competitor discounting and rebating in the standard IG segment can permanently compress realized prices and margins for legacy products. That structural pricing pressure risks long-term revenue and volume for BIVIGAM and similar SKUs absent durable differentiation or cost offset.
Elevated DSOs And Channel DislocationPersistently high DSOs lengthen cash conversion cycles and tie up liquidity, forcing higher working-capital funding or slower reinvestment. If distributor ordering patterns and channel inventories normalize slowly, elevated receivables could weigh on operational flexibility for months.
Rising Leverage Versus Recent YearsDebt rising materially over a short period reduces financial optionality. Moderate leverage limits buffer for adverse scenarios, increases fixed obligations, and could constrain R&D, M&A or buybacks if growth or margins disappoint, raising long-term execution risk.
ADMA Biologics News
ADMA FAQ
What was ADMA Biologics Inc’s price range in the past 12 months?
ADMA Biologics Inc lowest stock price was $7.21 and its highest was $20.46 in the past 12 months.
What is ADMA Biologics Inc’s market cap?
ADMA Biologics Inc’s market cap is $2.12B.
When is ADMA Biologics Inc’s upcoming earnings report date?
ADMA Biologics Inc’s upcoming earnings report date is Nov 11, 2026 which is in 87 days.
How were ADMA Biologics Inc’s earnings last quarter?
ADMA Biologics Inc released its earnings results on Aug 05, 2026. The company reported $0.165 earnings per share for the quarter, beating the consensus estimate of $0.163 by $0.002.
Is ADMA Biologics Inc overvalued?
According to Wall Street analysts ADMA Biologics Inc’s price is currently Undervalued.
Does ADMA Biologics Inc pay dividends?
ADMA Biologics Inc does not currently pay dividends.
What is ADMA Biologics Inc’s EPS estimate?
ADMA Biologics Inc’s EPS estimate is 0.2.
How many shares outstanding does ADMA Biologics Inc have?
ADMA Biologics Inc has 223,984,680 shares outstanding.
What happened to ADMA Biologics Inc’s price movement after its last earnings report?
ADMA Biologics Inc reported an EPS of $0.165 in its last earnings report, beating expectations of $0.163. Following the earnings report the stock price went up 8.639%.
Which hedge fund is a major shareholder of ADMA Biologics Inc?
Currently, no hedge funds are holding shares in ADMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ADMA Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.00 (105.56% Upside)
$17.00 (105.56% Upside)
Blogger Sentiment
Bullish
ADMA Sentiment 63%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $150.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.22%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
22.53%
Trailing 12-Months
Company Description
ADMA Biologics Inc
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
ADMA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive operational and financial story driven by strong ASCENIV revenue growth (+24% YoY), meaningful margin expansion (gross margin up to 69% from 55%), improved adjusted EBITDA (+22% YoY), solid cash generation and a healthy balance sheet with active share repurchases. Offsetting risks discussed include a significant decline in legacy BIVIGAM volumes (management expects ~40%–50% decline vs 2025), ongoing competitive pricing pressure in the standard IG market, elevated working capital (inventory and receivables) and a higher effective tax rate. Management reiterated full-year guidance and highlighted clinical evidence and pipeline progress (SG-001), supporting confidence in the company’s growth trajectory despite near-term market headwinds.View all ADMA earnings summariesADMA Stock 12 Month Forecast
Average Price Target
$17.00
▲(105.56% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Protagonist Therapeutics
―
Immunovant
―
MoonLake Immunotherapeutics
―
―
Ownership Overview
3.54% Insiders
26.79% Mutual Funds
23.11% Other Institutional Investors
12.58% Public Companies and
Individual Investors